

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA KTE-X19 for treating relapsed or refractory mantle cell lymphoma in people who have received at least two previous lines of therapy**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

|                                                                                                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| No                                                                                                                                                                      |

|                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
| No issues have been identified so this is not relevant                                                              |

|                                                                                          |
|------------------------------------------------------------------------------------------|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
| No issues have been identified so this is not relevant                                   |

|                                                                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

No

**Approved by Associate Director (name):** .....Janet Robertson.....

**Date:** 13 February 2020